nach oben

Current Hepatology Reports

Erschienen in:

08.02.2019 | Management of Cirrhotic Patient (A Cardenas and P Tandon, Section Editors)

TIPS Indications and Contraindications—Pushing the Limits: Is Earlier Better?

verfasst von: José Ferrusquía-Acosta, Virginia Hernández-Gea

Erschienen in: Current Hepatology Reports | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To describe the main indications and contraindications of transjugular intrahepatic portosystemic shunt (TIPS) placement in patients with portal hypertension (PH).

Recent Findings

An adequate selection of patients helps to identify those who may benefit from TIPS in terms of survival. In patients with acute variceal bleeding and factors of poor prognosis, a pre-emptive use of TIPS is associated with significant reductions in treatment failure and mortality. Similarly, TIPS has shown to improve survival in a highly selected group of patients with cirrhosis and refractory ascites.

Summary

PH is a clinical syndrome associated with the appearance of certain complications which can lead to high morbidity and mortality. TIPS placement effectively reduces portal pressure improving the outcomes of patients who present severe and/or refractory complications of PH. However, an adequate selection of candidates seems to be a key factor for improving the outcomes of patients treated with TIPS.

Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573–82. https://doi.org/10.1038/nrgastro.2009.149.CrossRefPubMed

Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353:2254–61. https://doi.org/10.1056/NEJMoa044456.CrossRefPubMed

Ripoll C, Groszmann R, Garcia–Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481–8. https://doi.org/10.1053/j.gastro.2007.05.024.CrossRefPubMed

Abraldes J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003;37:902–8. https://doi.org/10.1053/jhep.2003.50133.CrossRefPubMed

Villanueva C, López-Balaguer JM, Aracil C, Kolle L, González B, Miñana J, et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol. 2004;40:757–65. https://doi.org/10.1016/j.jhep.2004.01.017.CrossRefPubMed

D’Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology. 2006;131:1611–24. https://doi.org/10.1053/j.gastro.2006.09.013.CrossRefPubMed

Bureau C, Garcia-Pagan JC, Otal P, Pomier-Layrargues G, Chabbert V, Cortez C, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology. 2004;126:469–75. https://doi.org/10.1053/j.gastro.2003.11.016.CrossRefPubMed

Hernández-Guerra M, Turnes J, Rubinstein P, Olliff S, Elias E, Bosch J, et al. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology. 2004;40:1197–202. https://doi.org/10.1002/hep.20436.CrossRefPubMed

Thornburg B, Desai K, Hickey R, Kulik L, Ganger D, Baker T, et al. Portal vein recanalization and transjugular intrahepatic portosystemic shunt creation for chronic portal vein thrombosis: technical considerations. Tech Vasc Interv Radiol. 2016;19:52–60. https://doi.org/10.1053/j.tvir.2016.01.006.CrossRefPubMed

10.

Salem R, Vouche M, Baker T, Herrero JI, Caicedo JC, Fryer J, et al. Pretransplant portal vein recanalization—transjugular intrahepatic portosystemic shunt in patients with complete obliterative portal vein thrombosis. Transplantation. 2015;99:2347–55. https://doi.org/10.1097/TP.0000000000000729.CrossRefPubMed

11.

•• Thornburg B, Desai K, Hickey R, Hohlastos E, Kulik L, Ganger D, et al. Pretransplantation portal vein recanalization and transjugular intrahepatic portosystemic shunt creation for chronic portal vein thrombosis: final analysis of a 61-patient cohort. J Vasc Interv Radiol. 2017;28:1714–1721.e2. https://doi.org/10.1016/j.jvir.2017.08.005 This study analyzed the safety and efficacy of portal vein recanalization followed by TIPS in patients with cirrhosis and PVT as a procedure that aims to improve liver transplantation candidacy. CrossRefPubMed

12.

D’Amico G. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology. 2003;38:599–612. https://doi.org/10.1053/jhep.2003.50385.CrossRefPubMed

13.

Carbonell N, Pauwels A, Serfaty L, Fourdan O, Lévy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology. 2004;40:652–9. https://doi.org/10.1002/hep.20339.CrossRefPubMed

14.

Chau T, Patch D, Chan YW, Nagral A, Dick R, Burroughs AK. “Salvage” transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology. 1998;114:981–7. https://doi.org/10.1016/S0016-5085(98)00640-4.CrossRefPubMed

15.

Azoulay D, Castaing D, Majno P, Saliba F, Ichaï P, Smail A, et al. Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. J Hepatol. 2001;35:590–7. https://doi.org/10.1016/S0168-8278(01)00185-4.CrossRefPubMed

16.

García-Pagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;362:2370–9. https://doi.org/10.1056/NEJMoa0910102.CrossRefPubMed

17.

Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L, Sierra A, Guevara C, Jiménez E, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology. 2004;40:793–801. https://doi.org/10.1002/hep.20386.CrossRefPubMed

18.

Garcia-Pagán JC, Di Pascoli M, Caca K, Laleman W, Bureau C, Appenrodt B, et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol. 2013;58:45–50. https://doi.org/10.1016/j.jhep.2012.08.020.CrossRefPubMed

19.

Thabut D, Pauwels A, Carbonell N, Remy AJ, Nahon P, Causse X, et al. Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results. J Hepatol. 2018;68:73–81. https://doi.org/10.1016/j.jhep.2017.09.002.CrossRef

20.

• Hernández-Gea V, Procopet B, Giráldez Á, Amitrano L, Villanueva C, Thabut D, et al. Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study. Hepatology. 2018. https://doi.org/10.1002/hep.30182 This multicenter, international, observational study confirmed the survival benefit of TIPS in a large cohort of patients with cirrhosis and acute VB at high risk for treatment failure.

21.

Lv Y, Zuo L, Zhu X, Zhao J, Xue H, Jiang Z, et al. Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study. Gut. 2018:gutjnl-2018-317057. https://doi.org/10.1136/gutjnl-2018-317057.

22.

Papatheodoridis GV, Goulis J, Leandro G, Patch D, Burroughs AK. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: a meta-analysis. Hepatology. 1999;30:612–22. https://doi.org/10.1002/hep.510300316.CrossRefPubMed

23.

Khan SA, Tudur Smith C, Williamson PR, Sutton R. Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis. Cochrane Database Syst Rev. 2006:CD000553. https://doi.org/10.1002/14651858.CD000553.pub2.

24.

de Franchis R. Expanding consensus in portal hypertension. J Hepatol. 2015;63:743–52. https://doi.org/10.1016/j.jhep.2015.05.022.CrossRefPubMed

25.

Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310–35. https://doi.org/10.1002/hep.28906.CrossRefPubMed

26.

Sauerbruch T, Mengel M, Dollinger M, Zipprich A, Rössle M, Panther E, et al. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy. Gastroenterology. 2015;149:660–668.e1. https://doi.org/10.1053/j.gastro.2015.05.011.CrossRefPubMed

27.

Holster IL, Tjwa ETTL, Moelker A, Wils A, Hansen BE, Vermeijden JR, et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β-blocker for prevention of variceal rebleeding. Hepatology. 2016;63:581–9. https://doi.org/10.1002/hep.28318.CrossRefPubMed

28.

Garcia–Pagán JC, Patch D. Trials and tribulations: the prevention of variceal rebleeding. Gastroenterology. 2015;149:528–31. https://doi.org/10.1053/j.gastro.2015.07.026.CrossRefPubMed

29.

Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol. 2003;38:69–89. https://doi.org/10.1016/S0168-8278(03)00007-2.CrossRef

30.

Rössle M. TIPS: 25 years later. J Hepatol. 2013;59:1081–93. https://doi.org/10.1016/j.jhep.2013.06.014.CrossRefPubMed

31.

Rössle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut. 2010;59:988–1000. https://doi.org/10.1136/gut.2009.193227.CrossRefPubMed

32.

•• Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 2017;152:157–63. https://doi.org/10.1053/j.gastro.2016.09.016 This study evaluates the use of TIPS using PTFE-covered stents in a selected population of patients with cirrhosis and refractory ascites. CrossRefPubMed

33.

Barange K, Péron J-M, Imani K, Otal P, Payen J-L, Rousseau H, et al. Transjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices. Hepatology. 1999;30:1139–43. https://doi.org/10.1002/hep.510300523.CrossRefPubMed

34.

Lo G-H, Liang H-L, Chen W-C, Chen M-H, Lai K-H, Hsu P-I, et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy. 2007;39:679–85. https://doi.org/10.1055/s-2007-966591.CrossRefPubMed

35.

Dhanasekaran R, West JK, Gonzales PC, Subramanian R, Parekh S, Spivey JR, et al. Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis. Am J Gastroenterol. 2010;105:635–41. https://doi.org/10.1038/ajg.2009.634.CrossRefPubMed

36.

Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut. 2000;47:288–95. https://doi.org/10.1136/gut.47.2.288.CrossRefPubMedPubMedCentral

37.

Guevara M, Ginès P, Bandi JC, Gilabert R, Sort P, Jiménez W, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology. 1998;28:416–22. https://doi.org/10.1002/hep.510280219.CrossRefPubMed

38.

Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol. 2002;14:1363–8.CrossRefPubMed

39.

Allegretti AS, Ortiz G, Cui J, Wenger J, Bhan I, Chung RT, et al. Changes in kidney function after transjugular intrahepatic portosystemic shunts versus large-volume paracentesis in cirrhosis: a matched cohort analysis. Am J Kidney Dis. 2016;68:381–91. https://doi.org/10.1053/j.ajkd.2016.02.041.CrossRefPubMedPubMedCentral

40.

Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40:55–64. https://doi.org/10.1002/hep.20262.CrossRefPubMed

41.

Luca A, Caruso S, Milazzo M, Marrone G, Mamone G, Crinò F, et al. Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology. 2012;265:124–32. https://doi.org/10.1148/radiol.12112236.CrossRefPubMed

42.

Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143:1253–1260.e4. https://doi.org/10.1053/j.gastro.2012.07.018.CrossRefPubMed

43.

Maruyama H, Okugawa H, Takahashi M, Yokosuka O. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol. 2013;108:568–74. https://doi.org/10.1038/ajg.2012.452.CrossRefPubMed

44.

Hibi T, Nishida S, Levi DM, Selvaggi G, Tekin A, Fan J, et al. When and why portal vein thrombosis matters in liver transplantation. Ann Surg. 2014;259:760–6. https://doi.org/10.1097/SLA.0000000000000252.CrossRefPubMed

45.

Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol. 2012;57:203–12. https://doi.org/10.1016/j.jhep.2011.12.034.CrossRefPubMed

46.

Ghabril M, Agarwal S, Lacerda M, Chalasani N, Kwo P, Tector AJ. Portal vein thrombosis is a risk factor for poor early outcomes after liver transplantation. Transplantation. 2016;100:126–33. https://doi.org/10.1097/TP.0000000000000785.CrossRefPubMed

47.

Urata J, Yamashita Y, Tsuchigame T, Hatanaka Y, Matsukawa T, Sumi S, et al. The effects of transjugular intrahepatic portosystemic shunt on portal hypertensive gastropathy. J Gastroenterol Hepatol. 1998;13:1061–7. https://doi.org/10.1111/j.1440-1746.1998.tb00571.x.CrossRefPubMed

48.

Kamath PS, Lacerda M, Ahlquist DA, McKusick MA, Andrews JC, Nagorney DA. Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis. Gastroenterology. 2000;118:905–11. https://doi.org/10.1016/S0016-5085(00)70176-4.CrossRefPubMed

49.

Mezawa S, Homma H, Ohta H, Masuko E, Doi T, Miyanishi K, et al. Effect of transjugular intrahepatic portosystemic shunt formation on portal hypertensive gastropathy and gastric circulation. Am J Gastroenterol. 2001;96:1155–9. https://doi.org/10.1016/S0002-9270(01)02257-2.CrossRefPubMed

50.

European Association for the Study of the Liver. EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol. 2016;64:179–202. https://doi.org/10.1016/j.jhep.2015.07.040.CrossRef

51.

Perelló A, García-Pagán JC, Gilabert R, Suárez Y, Moitinho E, Cervantes F, et al. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology. 2002;35:132–9. https://doi.org/10.1053/jhep.2002.30274.CrossRefPubMed

52.

Garcia–Pagán JC, Heydtmann M, Raffa S, Plessier A, Murad S, Fabris F, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology. 2008;135:808–15. https://doi.org/10.1053/j.gastro.2008.05.051.CrossRefPubMed

53.

Seijo S, Plessier A, Hoekstra J, Dell’Era A, Mandair D, Rifai K, et al. Good long-term outcome of Budd-Chiari syndrome with a step-wise management. Hepatology. 2013;57:1962–8. https://doi.org/10.1002/hep.26306.CrossRefPubMed

54.

• Bissonnette J, Garcia-Pagán JC, Albillos A, Turon F, Ferreira C, Tellez L, et al. Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension. Hepatology. 2016;64:224–31. https://doi.org/10.1002/hep.28547 This retrospective study evaluates the efficacy and safety of TIPS in patients with idiopathic non-cirrhotic portal hypertension. CrossRefPubMed

55.

Siramolpiwat S, Seijo S, Miquel R, Berzigotti A, Garcia-Criado A, Darnell A, et al. Idiopathic portal hypertension: natural history and long-term outcome. Hepatology. 2014;59:2276–85. https://doi.org/10.1002/hep.26904.CrossRefPubMed

56.

Hernández-Gea V, Baiges A, Turon F, Garcia-Pagán JC. Idiopathic portal hypertension. Hepatology. 2018;68:2413–23. https://doi.org/10.1002/hep.30132.CrossRefPubMed

57.

Senzolo M, Tibbals J, Cholongitas E, Triantos CK, Burroughs AK, Patch D. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther. 2006;23:767–75. https://doi.org/10.1111/j.1365-2036.2006.02820.x.CrossRefPubMed

58.

Qi X, Han G, Yin Z, He C, Wang J, Guo W, et al. Transjugular intrahepatic portosystemic shunt for portal cavernoma with symptomatic portal hypertension in non-cirrhotic patients. Dig Dis Sci. 2012;57:1072–82. https://doi.org/10.1007/s10620-011-1975-5.CrossRefPubMed

59.

Fanelli F, Angeloni S, Salvatori FM, Marzano C, Boatta E, Merli M, et al. Transjugular intrahepatic portosystemic shunt with expanded-polytetrafuoroethylene-covered stents in non-cirrhotic patients with portal cavernoma. Dig Liver Dis. 2011;43:78–84. https://doi.org/10.1016/j.dld.2010.06.001.CrossRefPubMed

60.

Luo X, Nie L, Zhou B, Yao D, Ma H, Jiang M, et al. Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension in noncirrhotic patients with portal cavernoma. Gastroenterol Res Pract. 2014;2014:1–8. https://doi.org/10.1155/2014/659726.CrossRef

61.

Klinger C, Riecken B, Schmidt A, De Gottardi A, Meier B, Bosch J, et al. Transjugular portal vein recanalization with creation of intrahepatic portosystemic shunt (PVR-TIPS) in patients with chronic non-cirrhotic, non-malignant portal vein thrombosis Transjuguläre Pfortaderrekanalisation mit intrahepatischem portosystemischem. Z Gastroenterol. 2018;56:221–37. https://doi.org/10.1055/s-0043-121348.CrossRefPubMed

62.

Azoulay D, Castaing D, Lemoine A, Hargreaves GM, Bismuth H. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation. Bone Marrow Transplant. 2000;25:987–92. https://doi.org/10.1038/sj.bmt.1702386.CrossRefPubMed

63.

Campos-Varela I, Castells L, Dopazo C, Pérez-Lafuente M, Allende H, Len O, et al. Transjugular intrahepatic portosystemic shunt for the treatment of sinusoidal obstruction syndrome in a liver transplant recipient and review of the literature. Liver Transpl. 2012;18:201–5. https://doi.org/10.1002/lt.22351.CrossRefPubMed

64.

Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology. 2005;41:386–400. https://doi.org/10.1002/hep.20559.CrossRefPubMed

65.

Riggio O, Angeloni S, Salvatori FM, De Santis A, Cerini F, Farcomeni A, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008;103:2738–46. https://doi.org/10.1111/j.1572-0241.2008.02102.x.CrossRefPubMed

66.

Bai M, Qi X, Yang Z, Yin Z, Nie Y, Yuan S, et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review. J Gastroenterol Hepatol. 2011;26:943–51. https://doi.org/10.1111/j.1440-1746.2011.06663.x.CrossRefPubMed

67.

Wang Q, Lv Y, Bai M, Wang Z, Liu H, He C, et al. Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding. J Hepatol. 2017;67:508–16. https://doi.org/10.1016/j.jhep.2017.05.006.CrossRefPubMed

68.

Stents P, Miraglia R, Maruzzelli L, Amico MD, Luca A, Tuzzolino F, et al. Portosystemic shunts in patients with cirrhosis with refractory ascites: comparison of clinical outcomes by using 8- and 10-mm. Radiology. 2017;284:281–8. https://doi.org/10.1148/radiol.2017161644.CrossRef

69.

Moitinho E, Escorsell À, Bandi J, Salmerón J, García–Pagán J, Rodés J, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 1999;117:626–631. doi:https://doi.org/10.1016/S0016-5085(99)70455-5.

70.

Bambha K, Kim WR, Pedersen R, Bida JP, Kremers WK, Kamath PS. Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. Gut. 2008;57:814–20. https://doi.org/10.1136/gut.2007.137489.CrossRefPubMed

71.

Lecleire S, Di Fiore F, Merle V, Hervé S, Duhamel C, Rudelli A, et al. Acute upper gastrointestinal bleeding in patients with liver cirrhosis and in noncirrhotic patients: epidemiology and predictive factors of mortality in a prospective multicenter population-based study. J Clin Gastroenterol. 2005;39:321–7. https://doi.org/10.1097/01.mcg.0000155133.50562.c9.CrossRefPubMed

72.

Ripoll C, Bañares R, Rincón D, Catalina M-V, Lo Iacono O, Salcedo M, et al. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD era. Hepatology. 2005;42:793–801. https://doi.org/10.1002/hep.20871.CrossRefPubMed

73.

Thomopoulos K, Theocharis G, Mimidis K, Lampropoulou-Karatza C, Alexandridis E, Nikolopoulou V. Improved survival of patients presenting with acute variceal bleeding. Prognostic indicators of short- and long-term mortality. Dig Liver Dis. 2006;38:899–904. https://doi.org/10.1016/j.dld.2006.08.002.CrossRefPubMed

74.

Avgerinos A, Armonis A, Stefanidis G, Mathou N, Vlachogiannakos J, Kougioumtzian A, et al. Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis. Hepatology. 2004;39:1623–30. https://doi.org/10.1002/hep.20236.CrossRefPubMed

75.

Reverter E, Tandon P, Augustin S, Turon F, Casu S, Bastiampillai R, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. Gastroenterology. 2014;146:412–419.e3. https://doi.org/10.1053/j.gastro.2013.10.018.CrossRefPubMed

76.

Bureau C, Métivier S, D’Amico M, Péron JM, Otal P, Pagan JCG, et al. Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS. J Hepatol. 2011;54:901–7. https://doi.org/10.1016/j.jhep.2010.08.025.CrossRefPubMed

77.

Chalasani N, Clark WS, Martin LG, Kamean J, Khan MA, Patel NH, et al. Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting. Gastroenterology. 2000;118:138–44. https://doi.org/10.1016/S0016-5085(00)70422-7.CrossRefPubMed

78.

Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol. 2009;104:2458–66. https://doi.org/10.1038/ajg.2009.321.CrossRefPubMed

79.

Angermayr B, Cejna M, Karnel F, Gschwantler M, Koenig F, Pidlich J, et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut. 2003;52:879–85. https://doi.org/10.1136/gut.52.6.879.CrossRefPubMedPubMedCentral

Titel: TIPS Indications and Contraindications—Pushing the Limits: Is Earlier Better?
verfasst von: José Ferrusquía-Acosta
Virginia Hernández-Gea
Publikationsdatum: 08.02.2019
Verlag: Springer US
Erschienen in: Current Hepatology Reports / Ausgabe 1/2019
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-019-00453-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

TIPS Indications and Contraindications—Pushing the Limits: Is Earlier Better?

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Portal Hypertension after Liver Transplantation—Causes and Management

Predicting Future Complications of Cirrhosis

Prevention and Management of Hepatitis B in Healthcare Professionals

Non-invasive Measurement of Portal Pressure

Future Pharmacological Therapies of Portal Hypertension

Obscure Gastrointestinal Bleeding in Cirrhosis: Work-up and Management

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin